Combination treatment for nicotine dependence: State of the science

Substance Use and Misuse

Volumn 40, Issue 13-14, 2005, Pages 1923-1943

  Ingersoll, Karen S ^a,b,c   Cohen, Jessye ^a,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bupropion; Multimodal treatment; Nicotine dependence; Smoking cessation; Smoking reduction

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; FLUOXETINE; MECAMYLAMINE; METHADONE; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PAROXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUNSELING; DEPRESSION; DROWSINESS; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; METHADONE TREATMENT; NICOTINE REPLACEMENT THERAPY; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SMOKING; SMOKING CESSATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TIC; TOBACCO DEPENDENCE; TRAINING; WEIGHT GAIN; XEROSTOMIA;

BEHAVIOR THERAPY; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 31544438807     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080500294817     Document Type: Review

References (62)

1. Ahmadi, J., Ashkani, H., Ahmadi, M., Ahmadi, N. (2003). Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of Substance Abuse Treatment 24:251-255.
2. Balfour, D. J. (2001). The pharmacology underlying pharmacotherapy for tobacco dependence: A focus on bupropion. International Journal of Clinical Practice 55:53-57.
3. Benowitz, N. L. (1999). The biology of nicotine dependence; from the 1988 Surgeon General's Report to the present and into the future. Nicotine & Tobacco Research 1:S159-S163.
4. Biberman, R., Neumann, R., Katzir, I., Gerber, Y. (2003). A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 98:1403-1407.
5. Blondal, T., Gudmundsson, L. J., Tomasson, K., Jonsdottir, D., Hilmarsdottir, H., Kristjansson, F., Nilsson, F., Bjornsdottir, U. S. (1999). The effects of fluoxetine combined with nicotine inhalers in smoking cessation - a randomized trial. Addiction 94:1007-1015.
6. Bohadana, A., Nilsson, F., Rasmussen, K., & Mayo, M. S. (2000). Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Archives of Internal Medicine 160:3128-3134.
7. Burton, S. L., Gitman, J. G., Shiffman, S., and Epidemiology Branch, National Center for Chronic Disease Prevention and Health Promotion, CDC. Use of FDA-approved pharmacologic treatments for tobacco dependence - United States, 1984-1998 (2000). MMWR 49:665-668.
8. Covey, L. S., Glassman, A. H., Stetner, F., Rivelli, S., Stage, K. (2003). A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. The American Journal of Psychiatry 159:1731-1737.
9. Croghan, G. A., Sloan, J. A., Croghan, I. T., Novotny, P., Hurt, R., DeKrey, W. L., Mailliard, J. A., Ebbert, L. P., Swan, D. K., Walsh, D. J., Wiesenfeld, M., Levitt, R., Stella, P., Johnson, P. A., Tschetter, L. K., Lprinzi, C. (2003). Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine & Tobacco Research 5:181-187.
10. da Costa, C. L., Younes, R. N., Lourenco, M. T. C. (2002). Stopping smoking: A prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122:403-408.
11. DeGraff, A. C., Jr. (2002). Pharmacologic therapy for nicotine addiction. Chest 122:392-394.
12. Department of Health and Human Services, Public Health Service. (1988). The Health Consequences of Smoking: Nicotine Addiction. A report of the Surgeon General, DHHS, (CDC) Publication No. 88-8406. Washington, DC: Government Printing Office.
13. Etter, J.-F., Laszlo, E., Zellweger, J-P., Perrot, C., Perneger, T. V. (2002). Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. Journal of Clinical Psychophannacology 22:487-494.
14. Etter, J-F., le Houezec, J., Landfeldt, B. (2003). Impact of messages on comcomitant use of nicotine replacement therapy and cigarettes: A randomized trial on the Internet. Addiction 98:941-950.
15. Fiore, M. C., Bailey, W. C., Cohen, S. J. et al. (2000). Treating tobacco use and dependence. AHQR publication No. 00-0032. Rockville, MD: US Department of Health and Human Services, Public Health Service.
16. Gold, M. S., Herkov, M. J. (1998). Tobacco smoking and nicotine dependence: biological basis for pharmacotherapy from nicotine to treatments that prevent relapse. Journal of Addictive Diseases 17:7-21.
17. Gourlay, S. G., Benowitz, N. L. (1995). Is clonidine an effective smoking cessation therapy? Drugs 50:197-207.
18. Hall, S. M., Reus, V. I., Munoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., Triffleman, E. (1998). Nortriptyline and cognitive behavioral therapy in the treatment of cigarette smoking. Archives of General Psychiatry 55:683-690.
19. Haustein K. O. (2003). Bupropion: Pharmacological and clinical profile in smoking cessation. International Journal of Clinical Pharmacology and Therapeutics 41:56-66.
20. Hays, J. T., Ebbert, J. O. (2003). Bupropion for the treatment of tobacco dependence. Guidelines for balancing risks and benefits. CNS Drugs 17:71-83.
21. Hays, J., Taylor, M. D. (2000). Tobacco dependence treatment in patients with heart and lung disease: Implications for intervention and review of pharmacological therapy. Journal of Cardiopulmonary Rehabilitation 20:215-223.
22. Hitsman, B., Spring, B., Borrelli, B., Niaura, R., Papandonatos, G. D. (2001). Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine. Experimental and Clinical Psychopharmacology 9:355-362.
23. Holm, K., Spencer, C. M. (2000). Bupropion: A review of its use in the management of smoking cessation. Drugs 59:1007-1024.
24. Hughes, J. R., Goldstein, M. C., Hurt, R. D., Shiffman, S. (1999). Recent advances in the pharmacotherapy of smoking. Journal of the American Medical Association 281:72-76.
25. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., Swan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine & Tobacco Research 5:13-26.
26. Hurt, R. D., Krook, J. E., Craghan, I. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Kardinal, C. G., Knost, J. A., Tirona, M. R., Addo, F., Morton, R. F., Michalak, J. C., Schaefer, P. L., Porter, P. A., Stella, P. J. (2003). Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. Journal of Clinical Oncology 21:914-920.
27. Jamerson, B. D., Nides, M., Jorenby, D. E., Donahue, R., Garrett, P., Johnston, J. A., Fiore, M. C., Rennard, S. I., Leischow, S. J. (2001). Late-term smoking cessation despite initial failure: An evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clinical Therapeutics 23:744-752.
28. Jorenby, D. E. (2002). Clinical efficacy of bupropion in the management of smoking cessation. Drugs 62:25-35.
29. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., Fiore, M. C., Baker, T. B. (2003). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 340:685-691.
30. Karnath, B. (2002). Smoking cessation. American Journal of Medicine 112:399-405.
31. Killen, J. D., Fortmann, S. P., Schatzberg, A. F., Hayward, C., Sussman, L., Rothman, M., Strausberg, L., Varady, A. (2000). Nicotine patch and paroxetine for smoking cessation. Journal of Consulting and Clinical Psychology 68:883-889.
32. Koren, G. (2001). Nicotine replacement therapy during pregnancy. Canadian Family Physician 47:1971-1972.
33. Macleod, Z. R., Charles, M. A., Arnaldi, V. C., Adams, I. M. (2003). Telephone counselling as an adjunct to nicotine patches in smoking cessation: A randomised controlled trial. Medical Journal of Australia 179:349-352.
34. Molyneux, A., Lewis, S., Leivers, U., Anderton, A., Antoniak, M., Brackenridge, A., Nilsson, F., McNeill, A., West, R., Moxham, J., Britton, J. (2003). Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax 58:484-488.
35. Nardini, S. (2001). Smoking cessation: The role of Bupropion among new pharmacologic agents. Monaldi Archive for Chest Diseases 56:467-472.
36. Okuyemi, K. S., Ahluwalia, J. S., Harris, K. J. (2000). Pharmacotherapy of smoking cessation. Archives of Family Medicine 9:270-281.
37. Oncken C. A., Kranzler, H. R. (2003). Pharmacotherapies to enhance smoking cessation during pregnancy. Drug & Alcohol Review 22:191-202.
38. Peters, M. J., Morgan, L. C. (2002). The pharmacotherapy of smoking cessation. Medical Journal of Australia 176:486-490.
39. Picciotto, M. R. (1998). Common aspects of the action of nicotine and other drugs of abuse. Drug and Alcohol Dependence 51:165-172.
40. Pierce, J. P., Gilpin, E. A. (2003). A minimum 6-month prolonged abstinence should be required for evaluation smoking cessation trials. Nicotine & Tobacco Research 5:151-153.
41. Prochazka, A. V., Weaver, M. J., Keller, R. T., Freyer, G. E., Licari, P. A., Lofaso, D. (1998). A randomized trial of nortriptyline for smoking cessation. Archives of Internal Medicine 158:2035-2039.
42. Richmond, R. L., Harris, K., de Almeida Neto, A. (1994). The transdermal nicotine patch: Results of a randomised placebo-controlled trial. The Medical Journal of Australia 161:130-135.
43. Richmond, R. L., Kehoe, L., Almeida Neto, A. C. (1997). Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: One year outcome. Addiction 92:27-31.
44. Richmond, R., Zwar, N. (2003). Review of bupropion for smoking cessation. Drug & Alcohol Review 22:203-220.
45. Rollnick, S., Mason, P., Butler, C. (1999). Health Behavior Change. London: Churchill Livingstone.
46. Rolnick, S. J., Klevan, D., Cherney, L., Lando, H. (1997). Nicotine replacement therapy in a group model HMO. HMO Practice 11:34-37.
47. Rose, J. E., Behm, F. M., Westman, E. C. (1998). Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Experimental and Clinical Psychopharmacology 6:331-343.
48. Schauffler, H. H., Mordawsky, J. K., McMenamin, S. (2001). Adoption of the AHCPR Clinical Practice Guideline for Smoking Cessation: A Survey of California's HMOs. American Journal of Preventive Medicine 21:153-161.
49. Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M. E., Rawson, R. A., Ling, W. (2002). Smoking cessation in methadone maintenance. Addiction 97:1317-1328.
50. Silagy, C., Lancaster, T., Stead, L. F., Mant, D., Fowler, G. (2002). Nicotine replacement therapy for smoking cessation. Cochrane Database System Review 4.
51. Simon, J. A., Carmody, T. P., Hudes, E. S., Snyder, E., Murray, J. (2003). Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdemial nicotine replacement: A randomized trial. American Journal of Medicine 114:555-562.
52. Sims, T. H., Fiore, M. C. (2002). Pharmacotherapy for treating tobacco dependence: What is the ideal duration of therapy? CNS Drugs 16:653-662.
53. Steele, C. (2000). Zyban: An effective treatment for nicotine addiction. Hospital Medicine 61:785-788.
54. Swan, G. E., McAfee, T., Curry, S. J., Jack L. M., Javitz, H., Dacey, S., Bergman, K. (2003). Effectiveness of bupropion sustained release for smoking cessation in a health care setting: A randomized trial. Archives of Internal Medicine 163:2337-2344.
55. Swanson, N. A., Burroughs, C. C., Long, M. A., Lee, R. W. (2003). Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release bupropion, or both. Military Medicine 168:830-834.
56. Tønnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., van Spiegel, P. I., Hider, A., Sweet, R., Townsend, J. (2003). A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine 254:184-192.
57. Thomson, C. C., Rigotti, N. A. (2003). Hospital-and clinic-based smoking cessation interventions for smokers with cardiovascular disease. Progressive Cardiovascular Disease 45:459-479.
58. Wagena, E. J., Zeegers, M. P., van Schayck, C. P., Wouters, E. F. (2003). Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Safety 26:381-403.
59. Watts, S. A., Noble, S. L., Smith, P. O., Disco, M. (2002). First-line pharmacotherapy for tobacco use and dependence. Journal of the American Board of Family Practice 15:489-497.
60. Wennike, P., Danielsson, T., Landfeldt, B., Westin, A., Tønnesen, P. (2003). Smoking reduction promotes smoking cessation: Results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 98:1395-1402.
61. Wiggers, L. C., Smets, E. M., de Haes, J. C., Peters, R. J., Legemate, D. A. (2003). Smoking cessation interventions in cardiovascular patients. European Journal of Vascular & Endovascular Surgery 26:467-475.
62. World Health Organization. (2002). The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization.